Evaluating the state of cardiac health requires extensive assessment of a diverse set of functional outputs. Novoheart’s mini-Heart Platform is the ideal solution, consisting of 3 distinct tissue formats fabricated from human stem cell-derived cardiomyocytes that are designed for assessing specific cardiac functional outputs. Data acquired by the mini-Heart Platform has successfully led to a series of pre-clinical candidates as well as Investigational New Drug (IND) and Fast Track Designation (FTD) applications approved by the FDA, and ongoing clinical trials.

• Human-derived platform offers clinically translatable relevance
• Readily adaptable and customizable for induced Pluripotent Stem Cell (iPSC) disease

       modeling and drug screening services

• Supported by commercially available hardware and software to maximize sensitivity, accuracy, and throughput
• Optimized cell and matrix bullet kits are available to engineer cardiac tissues in-house, using our commercial bioreactor systems and custom mini-Heart cartridges